Mycotoxin Contamination in Herbal Ingredients: What Your Analytical Testing Laboratory Should Be Checking

A 2019 multi-market survey published in Toxins found detectable aflatoxin contamination in more than 60% of commercial turmeric and ginger samples tested across multiple sourcing regions. Not marginal traces — concentrations that would trigger regulatory action in the EU and, in several cases, exceed the FDA’s general action level. If you’re sourcing botanical raw materials without routine mycotoxin screening, you’re almost certainly accepting some of those lots.

The herbal supplement industry has made real progress on heavy metals and pesticide residues over the past decade. Mycotoxins, though, still get treated as an afterthought by a lot of procurement and quality teams. That’s a mistake with consequences that range from product recalls to serious harm for end consumers — and increasingly, direct liability for the manufacturer when a contaminated batch makes it through incoming inspection.

Why Herbal Botanicals Carry Higher Mycotoxin Risk Than Most Ingredients

Mycotoxins are secondary metabolites produced by molds — principally Aspergillus, Fusarium, and Penicillium species. They form under specific conditions: warm temperatures, high humidity, and physical stress on plant material. Which, not coincidentally, describes the growing environments and post-harvest handling for a large proportion of the botanical ingredients moving through global supply chains.

Botanicals grown in tropical and subtropical regions — turmeric, ginger, ashwagandha, black pepper, licorice root, fenugreek, dried mushroom powders — are inherently higher risk. But it’s not just geography. Drying practices matter. So does storage humidity during transit and the time materials spend in inadequately controlled warehouses. By the time a raw material reaches a supplement manufacturer in North America or Europe, it may have passed through three or four handling points, each one a potential contamination window.

There’s a subtler issue that matters specifically for analytical work: mycotoxins are chemically stable. They survive many processing conditions that kill the mold itself — including roasting, grinding, and mild heat treatments. So the presence of visible mold on incoming material is one signal, but the absence of visible mold growth or an elevated total aerobic plate count does not mean mycotoxins aren’t present. You need direct chemical analysis. Full stop.

The Four Mycotoxin Classes That Warrant Routine Screening

Not all mycotoxins carry equal risk, and not all botanical categories carry equal contamination profiles. A well-designed screening panel for herbal raw materials should cover at minimum:

Aflatoxins (B1, B2, G1, G2) are the priority concern for most botanicals. Aflatoxin B1 is classified as a Group 1 human carcinogen by the International Agency for Research on Cancer (IARC) — not “possible” or “probable,” but sufficient evidence in humans. The EU sets the limit for aflatoxin B1 in dried herbs and spices at 5 µg/kg, with total aflatoxins (B1 + B2 + G1 + G2) capped at 10 µg/kg under Regulation EC 1881/2006 and its amendments. The FDA’s general action level for total aflatoxins in food is 20 µg/kg (20 ppb), though enforcement actions for supplement products have occurred at lower concentrations when vulnerable consumer populations are involved.

Ochratoxin A (OTA) is nephrotoxic and a Group 2B possible carcinogen (IARC). It’s particularly prevalent in licorice root, dried figs, and root-derived botanicals more broadly. The EU limit for OTA in dried herbs and spices is 30 µg/kg. Long-term low-level OTA exposure is associated with Balkan endemic nephropathy — a progressive chronic kidney disease — which is part of why European regulators treat even sub-50 µg/kg OTA levels with real seriousness.

Fumonisins (B1 and B2) are primarily associated with corn-derived ingredients but appear in botanical raw materials processed in facilities that also handle cereal crops. The EU limits total fumonisins in maize at 4,000 µg/kg for unprocessed grain; while specific limits aren’t always codified for every botanical matrix, fumonisin B1 and B2 belong in any comprehensive screening panel for ingredients with grain co-processing history.

Deoxynivalenol (DON) and zearalenone round out a practical four-class panel. DON — sometimes called vomitoxin — shows up in botanical materials that share processing infrastructure with cereal grains. Zearalenone has well-documented estrogenic activity and is increasingly scrutinized in products marketed for women’s health and hormone support formulations. If your finished product positioning touches either of those categories, zearalenone screening is essentially required for due diligence.

Regulatory Limits Across Markets — and Why the Gaps Create Real Risk

The compliance picture for mycotoxins in herbal ingredients is fragmented, and that fragmentation creates risk for companies selling into multiple markets simultaneously.

Under USP General Chapter <561> (Articles of Botanical Origin), botanical ingredients used in dietary supplements must meet identity, purity, and quality standards. Mycotoxin requirements are incorporated by reference through USP General Chapter <2023> and relevant monographs. The 2023 revision of NSF/ANSI 173 — the primary US voluntary standard for dietary supplements — explicitly includes mycotoxin acceptance criteria for botanical ingredients, bringing US practice closer in line with EU requirements.

The FDA’s 21 CFR Part 111 (dietary supplement cGMP) requires a written hazard analysis for each raw material. Aflatoxins and other mycotoxins qualify as chemical hazards under the regulation’s framework. If your incoming material specifications don’t include mycotoxin acceptance limits, you have a documentation gap that’s directly visible during an FDA 483 inspection — and it’s one that’s been cited with increasing frequency over the last three inspection cycles.

The EU situation, governed by Regulation EC 1881/2006 and subsequent Commission Regulations, is where the most significant market-access risk concentrates. The EU’s aflatoxin B1 limit for dried herbs (5 µg/kg) is four times stricter than the FDA’s total aflatoxin action level (20 µg/kg). Material that passes US specifications can fail EU requirements. Companies that discover this at the point of export — rather than at incoming inspection — face either a lot rejection or a costly remediation process.

The Codex Alimentarius Commission’s standards are worth knowing even if you’re not selling into Codex member markets directly. Many Middle Eastern, Southeast Asian, and Latin American markets use Codex limits as their default reference point for import decisions. Specifying your incoming material limits against the strictest applicable standard — typically EU — protects you across most of those markets without requiring a separate specification matrix.

What to Demand from Your Analytical Testing Laboratory

The method your analytical testing laboratory uses matters, and the choice involves real tradeoffs between throughput, cost, sensitivity, and the defensibility of your results in a regulatory context.

ELISA and lateral flow immunoassays are widely used for rapid front-line screening. They’re cost-effective, high-throughput, and practical for quick release decisions on large incoming volumes. The limitation is specificity: immunoassay-based methods can produce false positives due to antibody cross-reactivity with structurally similar compounds in complex botanical matrices, and they’re not validated for regulatory submission in most jurisdictions. ELISA results are useful for triage; they shouldn’t be the sole basis for lot acceptance.

HPLC with fluorescence detection (HPLC-FLD) is the method codified in AOAC official methods for mycotoxins — including AOAC 991.31 for aflatoxins and AOAC 2007.01 for ochratoxin A. It’s significantly more specific than immunoassay and produces results that are defensible in regulatory submissions. Aflatoxins require derivatization (post-column with KBr oxidation or pre-column with trifluoroacetic acid) to produce adequate fluorescence signal. A properly equipped laboratory running validated AOAC methods will report limits of quantitation in the range of 0.5–1 µg/kg for aflatoxin B1 — well below the most stringent applicable limits.

LC-MS/MS (liquid chromatography tandem mass spectrometry) is the gold standard for multi-mycotoxin panels. A single validated LC-MS/MS run can simultaneously quantify 20–30 individual mycotoxins and their conjugated metabolites. This matters because “masked” mycotoxins — like deoxynivalenol-3-glucoside, a DON metabolite generated by the plant itself — are not detected by antibody-based methods but are biologically active and appear cleanly on LC-MS/MS. For comprehensive supplier qualification or market-entry testing into regulated markets, LC-MS/MS multi-residue panels are the right investment.

When evaluating an analytical testing laboratory for mycotoxin work on botanical raw materials, ask these questions directly:

• Is the laboratory ISO 17025-accredited for mycotoxin testing specifically in botanical matrices?
• Do their reported limits of quantitation (LOQs) sit below the acceptance criteria in your target markets?
• What is the laboratory’s matrix-matched recovery validation data for the botanical types you source?
• What sampling protocol do they recommend for your lot sizes, and is it aligned with ISO 24333 or AOAC sampling principles?

The last point is one that’s frequently overlooked. Mycotoxin distribution in bulk botanical raw materials is not uniform — contamination clusters in “hot spots,” meaning a poorly designed sampling protocol will miss contaminated portions of a lot even when the testing method is excellent. The ISO 2859-1 acceptance sampling framework and AOAC’s guidance on sample size and sample preparation both address this. An analytical testing laboratory with genuine expertise in botanicals should be able to walk you through a sampling strategy, not just a testing protocol.

Building Mycotoxin Risk Into Your Incoming Specification Before the Problem Finds You

Quality managers who handle mycotoxin risk well don’t react to failed finished-product tests. They’ve built screening into their incoming material release workflow, specified acceptance limits against the strictest regulatory market they supply, and qualified analytical testing laboratories with validated, matrix-specific methods for each botanical category they source.

For high-risk ingredients — turmeric, licorice root, ginger, ashwagandha, fenugreek, black pepper, dried mushroom powders — routine aflatoxin and OTA screening should be non-negotiable. For broader panels covering DON, zearalenone, and fumonisins, LC-MS/MS is worth the additional cost. And when a supplier offers to substitute their own in-house ELISA result for third-party analytical data, that’s precisely when to require independent verification.

The 20 µg/kg number in FDA guidance isn’t a target. It’s a ceiling. The companies building durable supplement brands are setting their incoming limits well below it.

---

Written by Nour Abochama, Quality Consultant, Ayah Labs. Learn more about our team

Talk to our team about raw material testing. Contact us

Related from our network

• Mycotoxin and Pesticide Screening for Supplement Raw Materials — Qalitex Laboratories provides ISO 17025-accredited analytical testing for botanical ingredients entering the US supplement market, including validated LC-MS/MS multi-mycotoxin panels.